KaloBios CF KB001A-05 A Phase 2, Randomized Double-Blind, Placebo-Controlled, Repeat-dose Study of KB001A in Subjects with Cystic Fibrosis Infected withPseudomonas Aeruginosa

Grants and Contracts Details

StatusFinished
Effective start/end date10/30/12 → 10/30/14

Funding

  • KaloBios Pharmaceuticals Incorporated: $48,359.00